Cyril Allouche

US·SEC (Form 4)

Revance Therapeutics, Inc.

Cumul. flow

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (6 ops.)

€87k

Latest filing published 19 Mar 2019 for Revance Therapeutics, Inc., €3,443.

Filing timeline

BuySale

Cyril Allouche

Insider track record

Disclosed buys

Disclosed sells

Signal history

Cyril Allouche: trading record in brief

Cyril Allouche discloses dealings in Revance Therapeutics, Inc. to SEC (Form 4). We count 14 filings; the first trade dates from 20 June 2018 and the latest from 18 March 2019.

Every open-market trade on record is a sale: 6 sales worth €87k. Besides market trades, the filings include 4 share grants and 2 option exercises. 2019 to date brings no purchases and 3 sales.

Most recently, on 19 March 2019, the filings show a share grant worth €3,443 in Revance Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Cyril Allouche

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Revance Therapeutics, Inc. (US)

Declarations14 total

◆
Cyril Allouche
Principal Accounting OfficerExecutives15 Mar 2019Revance Therapeutics, Inc.
3,893 USD19SEC
252 shares@ US$15.452.4% of flowCommon StockSEC:0001479290-19-000036:0
▼
Cyril Allouche
Principal Accounting OfficerExecutives18 Mar 2019Revance Therapeutics, Inc.
7,709 USD31SEC
498 shares@ US$15.484.8% of flowCommon StockSEC:0001479290-19-000036:1
◆
Cyril Allouche
Principal Accounting OfficerExecutives24 Jan 2019Revance Therapeutics, Inc.
0SEC
3,150 shares0Common StockSEC:0001479290-19-000015:0
◇
Cyril Allouche
Principal Accounting OfficerExecutives22 Jan 2019Revance Therapeutics, Inc.
8,344 USD20SEC
625 shares@ US$13.355.2% of flowCommon StockSEC:0001479290-19-000010:0
▼
Cyril Allouche
Principal Accounting OfficerExecutives22 Jan 2019Revance Therapeutics, Inc.
11,106 USD20SEC
625 shares@ US$17.776.9% of flowCommon StockSEC:0001479290-19-000010:1
▼
Cyril Allouche
Principal Accounting OfficerExecutives3 Jan 2019Revance Therapeutics, Inc.
7,305 USD19SEC
375 shares@ US$19.484.5% of flowCommon StockSEC:0001479290-19-000006:0
●
Cyril Allouche
Principal Accounting OfficerExecutives31 Dec 2018Revance Therapeutics, Inc.
6,416 USD19SEC
375 shares@ US$17.114.0% of flowCommon StockSEC:0001479290-19-000002:0
▼
Cyril Allouche
Principal Accounting OfficerExecutives20 Nov 2018Revance Therapeutics, Inc.
10,144 USD20SEC
491 shares@ US$20.666.2% of flowCommon StockSEC:0001479290-18-000121:0
◆
Cyril Allouche
Principal Accounting OfficerExecutives15 Nov 2018Revance Therapeutics, Inc.
5,436 USD19SEC
259 shares@ US$20.993.4% of flowCommon StockSEC:0001479290-18-000116:0
◇
Cyril Allouche
Principal Accounting OfficerExecutives9 Nov 2018Revance Therapeutics, Inc.
29,210 USD21SEC
2,188 shares@ US$13.3518.1% of flowCommon StockSEC:0001479290-18-000114:0
▼
Cyril Allouche
Principal Accounting OfficerExecutives9 Nov 2018Revance Therapeutics, Inc.
51,899 USD22SEC
2,188 shares@ US$23.7232.2% of flowCommon StockSEC:0001479290-18-000114:1
▼
Cyril Allouche
Principal Financial OfficerExecutives6 Jul 2018Revance Therapeutics, Inc.
11,142 USD12SEC
393 shares@ US$28.356.7% of flowCommon StockSEC:0001479290-18-000095:0
●
Cyril Allouche
Principal Financial OfficerExecutives29 Jun 2018Revance Therapeutics, Inc.
9,169 USD12SEC
393 shares@ US$23.335.6% of flowCommon StockSEC:0001479290-18-000093:0
◆
Cyril Allouche
Principal Financial OfficerExecutives20 Jun 2018Revance Therapeutics, Inc.
0SEC
250 shares0Common StockSEC:0001479290-18-000089:0

14 of 14 declarations

Cyril Allouche

Insider track record

Cyril Allouche: trading record in brief

Companies and markets linked to Cyril Allouche

Similar companies

Related executives